Biomarkers in renal cancer

Treatment options for primary and metastatic renal cancer are increasing. Accurate data from the pathological examination of renal cancer specimens aid clinicians in stratifying patients for surveillance and adjuvant therapies. This review focuses on biomarkers in diagnosis, prognosis and prediction of the biologic behavior of renal tumors which should be recorded in pathology reports and which are under investigation. Special emphasis is given to the use of immunohistochemical markers in differential diagnosis of various renal tumor subtypes. The relevance of cytogenetic and molecular findings is also discussed. The review includes the 2012 International Society for Urological Pathology Consensus conference recommendations.

[1]  H. Moch.  An overview of renal cell cancer: pathology and genetics. , 2013, Seminars in cancer biology.

[2]  Huanming Yang,et al.  Single-Cell Exome Sequencing Reveals Single-Nucleotide Mutation Characteristics of a Kidney Tumor , 2012, Cell.

[3]  H. Moch,et al.  Identification and functional characterization of pVHL-dependent cell surface proteins in renal cell carcinoma. , 2012, Neoplasia.

[4]  Holger Moch,et al.  Reassessing the current UICC/AJCC TNM staging for renal cell carcinoma. , 2009, European urology.

[5]  B. Delahunt,et al.  Renal Tumors: Diagnostic and Prognostic Biomarkers , 2013, The American journal of surgical pathology.

[6]  Andrew H. Beck,et al.  PAX8 expression reliably distinguishes pancreatic well-differentiated neuroendocrine tumors from ileal and pulmonary well-differentiated neuroendocrine tumors and pancreatic acinar cell carcinoma , 2011, Modern Pathology.

[7]  Lars Egevad,et al.  The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia , 2013, The American journal of surgical pathology.

[8]  P. Argani,et al.  A distinctive pediatric renal neoplasm characterized by epithelioid morphology, basement membrane production, focal HMB45 immunoreactivity, and t(6;11)(p21.1;q12) chromosome translocation. , 2001, The American journal of pathology.

[9]  T. H. van der Kwast,et al.  Epithelioid angiomyolipoma: a morphologically distinct variant that mimics a variety of intra-abdominal neoplasms. , 2011, Archives of pathology & laboratory medicine.

[10]  M. Amin,et al.  An immunohistochemical approach to the differential diagnosis of renal tumors. , 2005, Seminars in diagnostic pathology.

[11]  W. Kaelin,et al.  The VHL/HIF axis in clear cell renal carcinoma. , 2013, Seminars in cancer biology.

[12]  H. Moch,et al.  Loss of PBRM1 expression is associated with renal cell carcinoma progression , 2013, International journal of cancer.

[13]  H. Moch,et al.  VHL gene mutations and their effects on hypoxia inducible factor HIFα: identification of potential driver and passenger mutations. , 2011, Cancer research.

[14]  S. Bonsib.  Renal lymphatics, and lymphatic involvement in sinus vein invasive (pT3b) clear cell renal cell carcinoma: a study of 40 cases , 2006, Modern Pathology.

[15]  J. Cheville,et al.  The International Society of Urological Pathology (ISUP) Grading System for Renal Cell Carcinoma and Other Prognostic Parameters , 2013, The American journal of surgical pathology.

[16]  H. Moch,et al.  Current pathology keys of renal cell carcinoma. , 2011, European urology.

[17]  J. Larkin,et al.  Current and future systemic treatments for renal cell carcinoma. , 2013, Seminars in cancer biology.

[18]  R. Figlin,et al.  Identification of a 4-microRNA Signature for Clear Cell Renal Cell Carcinoma Metastasis and Prognosis , 2012, PloS one.

[19]  H. Moch,et al.  Tumor-associated macrophages subvert T-cell function and correlate with reduced survival in clear cell renal cell carcinoma , 2013, Oncoimmunology.

[20]  S. Signoretti,et al.  Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear‐cell renal cell carcinoma receiving vascular endothelial growth factor‐targeted therapy , 2010, BJU international.

[21]  A. Poprach,et al.  Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma , 2012, Journal of Translational Medicine.

[22]  K. Junker,et al.  Specific miRNA signatures are associated with metastasis and poor prognosis in clear cell renal cell carcinoma , 2011, World Journal of Urology.

[23]  M. Ladanyi,et al.  Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma: a distinctive tumor entity previously included among renal cell carcinomas of children and adolescents. , 2001, The American journal of pathology.

[24]  P. Tang,et al.  Clinical and molecular prognostic factors in renal cell carcinoma: what we know so far. , 2011, Hematology/oncology clinics of North America.

[25]  L. Sobin,et al.  TNM Classification of Malignant Tumours , 1987, UICC International Union Against Cancer.

[26]  M. Seto,et al.  Overexpression of miR‐210, a downstream target of HIF1α, causes centrosome amplification in renal carcinoma cells , 2011, The Journal of pathology.

[27]  B. Delahunt,et al.  Handling and Staging of Renal Cell Carcinoma: The International Society of Urological Pathology Consensus (ISUP) Conference Recommendations , 2013, The American journal of surgical pathology.

[28]  B. Delahunt,et al.  International Society of Urological Pathology (ISUP) consensus conference on renal neoplasia: rationale and organization. , 2013, The American journal of surgical pathology.

[29]  M. Ladanyi,et al.  Utilization of a TFE3 Break-apart FISH Assay in a Renal Tumor Consultation Service , 2013, The American journal of surgical pathology.

[30]  R. Bukowski,et al.  Biomarkers Predicting Outcome in Patients with Advanced Renal Cell Carcinoma: Results from Sorafenib Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial , 2010, Clinical Cancer Research.

[31]  A. Folpe,et al.  Distribution of Cytokeratins and Vimentin in Adult Renal Neoplasms and Normal Renal Tissue: Potential Utility of a Cytokeratin Antibody Panel in the Differential Diagnosis of Renal Tumors , 2005, The American journal of surgical pathology.

[32]  B. Delahunt.  Advances and controversies in grading and staging of renal cell carcinoma , 2009, Modern Pathology.

[33]  G. Kovacs,et al.  Cytogenetics of papillary renal cell tumors , 1991, Genes, chromosomes & cancer.

[34]  H. Moch,et al.  CDKNA2A mutation analysis, protein expression, and deletion mapping of chromosome 9p in conventional clear-cell renal carcinomas: evidence for a second tumor suppressor gene proximal to CDKN2A. , 2001, The American journal of pathology.

[35]  S. Bonsib.  T2 clear cell renal cell carcinoma is a rare entity: a study of 120 clear cell renal cell carcinomas. , 2005, The Journal of urology.

[36]  M. Ladanyi,et al.  Renal Carcinomas With the t(6;11)(p21;q12): Clinicopathologic Features and Demonstration of the Specific Alpha-TFEB Gene Fusion by Immunohistochemistry, RT-PCR, and DNA PCR , 2005, The American journal of surgical pathology.

[37]  E. Schröck,et al.  Specific loss of chromosomes 1, 2, 6, 10, 13, 17, and 21 in chromophobe renal cell carcinomas revealed by comparative genomic hybridization. , 1994, The American journal of pathology.

[38]  R. Arceci.  Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing , 2012 .

[39]  I. Sesterhenn,et al.  World health organization classifications of tumours. pathology and genetics of tumours of the urinary system and male genital organs , 2005 .

[40]  H. Moch,et al.  Loss of VHL and Hypoxia Provokes PAX2 Up-Regulation in Clear Cell Renal Cell Carcinoma , 2009, Clinical Cancer Research.

[41]  F. Waldman,et al.  Genetic aberrations detected by comparative genomic hybridization are associated with clinical outcome in renal cell carcinoma. , 1996, Cancer research.

[42]  A. Parwani.  A Novel Tumor Grading Scheme for Chromophobe Renal Cell Carcinoma: Prognostic Utility and Comparison With Fuhrman Nuclear Grade , 2011 .

[43]  V. Reuter,et al.  Alpha-methylacyl-CoA racemase as a marker in the differential diagnosis of metanephric adenoma , 2006, Modern Pathology.

[44]  H. Moch,et al.  Chromophobe Renal Cell Carcinoma: Histomorphologic Characteristics and Evaluation of Conventional Pathologic Prognostic Parameters in 145 Cases , 2008, The American journal of surgical pathology.

[45]  P. A. Futreal,et al.  Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma , 2010, Nature.

[46]  A. Gámez-Pozo,et al.  MicroRNA expression profiling of peripheral blood samples predicts resistance to first-line sunitinib in advanced renal cell carcinoma patients. , 2012, Neoplasia.

[47]  J. Cheville,et al.  Chromophobe Renal Cell Carcinoma: The Impact of Tumor Grade on Outcome , 2012, The American journal of surgical pathology.

[48]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of clear cell renal cell carcinoma , 2013, Nature.

[49]  Peter Bühlmann,et al.  Mining Tissue Microarray Data to Uncover Combinations of Biomarker Expression Patterns that Improve Intermediate Staging and Grading of Clear Cell Renal Cell Cancer , 2009, Clinical Cancer Research.

[50]  Ximing J. Yang,et al.  Renal Tubulocystic Carcinoma Is Closely Related to Papillary Renal Cell Carcinoma: Implications for Pathologic Classification , 2009, The American journal of surgical pathology.

[51]  G. Kristiansen,et al.  Relevance of periostin splice variants in renal cell carcinoma. , 2011, The American journal of pathology.

[52]  H. Moch,et al.  Diagnostic and prognostic molecular markers for renal cell carcinoma: a critical appraisal of the current state of research and clinical applicability. , 2009, European urology.

[53]  J. Eble.  Angiomyolipoma of kidney. , 1998, Seminars in diagnostic pathology.

[54]  P. Argani,et al.  Carbonic anhydrase IX expression in renal neoplasms: correlation with tumor type and grade. , 2010, American journal of clinical pathology.

[55]  A. Poprach,et al.  Identification of MicroRNAs associated with early relapse after nephrectomy in renal cell carcinoma patients , 2012, Genes, chromosomes & cancer.

[56]  S. Fuhrman,et al.  Prognostic significance of morphologic parameters in renal cell carcinoma , 1982, The American journal of surgical pathology.

[57]  Holger Moch,et al.  Epidermal growth factor receptor protein expression and genomic alterations in renal cell carcinoma , 2012, Cancer.

[58]  B. Delahunt,et al.  Grading of Clear Cell Renal Cell Carcinoma Should be Based on Nucleolar Prominence , 2011, The American journal of surgical pathology.

[59]  H. Moch,et al.  Defective infiltration of natural killer cells in MICA/B-positive renal cell carcinoma involves beta(2)-integrin-mediated interaction. , 2009, Neoplasia.

[60]  Steve Horvath,et al.  Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.